Advertisement Adhezion wins FDA clearance for SurgiSeal topical skin adhesive - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Adhezion wins FDA clearance for SurgiSeal topical skin adhesive

Adhezion Biomedical, a medical device company, has announced that the FDA has provided marketing clearance for its SurgiSeal topical skin adhesive.

SurgiSeal is said to be the first and only 2-octyl cyanoacrylate that does not require an activator. It is indicated for use in surgical and emergency applications.

Cyanoacrylate medical adhesives are designed to save time during wound closure, provide a flexible, water-resistant, microbial barrier coating, and eliminates the need for suture removal, the company said.

Pete Molinaro, CEO of Adhezion Biomedical, said: “SurgiSeal’s patented OctylFlex monomer process can be used in a wide array of topical product applications, addressing skin lacerations, incisions and plastic surgery. It meets the needs of surgeons and patients seeking less disruptive, more natural healing solutions that are both durable and versatile.”